Speciality: Pediatrics
Description:
A warm welcome to all the medical professionals in this session on an overview of short stature and Turner’s syndrome.
Short stature and Turner’s syndrome is caused due to growth hormone deficiency in babies. Short stature is a term applied to a child whose height is 2 standard deviations (SD) or more below the mean for children of that sex and chronologic age. It is a type of deficiency in children that hinders the height of the babies.
Turner syndrome is also a growth deficit condition that affects only females. It occurs when one of the X chromosomes (sex chromosomes) is missing or partially missing in females. Turner syndrome can cause a variety of medical and developmental problems, including short height, failure of the ovaries to develop, and heart defects. Learn about it through various case studies
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Parkinson patient's gait is restored by a spinal cord stimulator.
2.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
3.
Next Day Mood Is Affected by Ability to Recover From Work.
4.
Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness
5.
Children with cancer experience much less pain at home when using a pain monitoring app.
1.
Unlocking the Potential of Leukemia Treatment: A New Hope for Patients
2.
Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology
3.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
4.
The Lowdown on Darbepoetin: Understanding Its Uses and Side Effects
5.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation